Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

Oncogenic YAP accelerates S-phase entry by shortening G1, leading to replication stress and sensitivity to CHK1 inhibition.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a ...

While their functions are diverse, myosins are similar in structure. NMII is so much like cardiac myosin, which keeps the ...

Panelists discuss recent trial data demonstrating that a novel agent not only slows lung function decline but also delays ...

SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

VIDEO: Future developments in the JAK inhibitor spaceEditor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the ...